Neuronal nicotinic acetylcholine receptor ligands as potential analgesics

Bibliography

• DAVIS L, POLLOCK LJ, STONE T: Visceral pain. Surg. Cynecol. Obstet. (1932) 55:418–426.
   Google Scholar
• TRIPATHI HL, MARTIN BR, ACETO MD: Nicotine-induced antinociception in rats and mice: correlation with nicotine brain levels. Pharmacol Exp. Ther. (1982) 221:91–96.
   PubMed Web of Science ®Google Scholar
• CAGGIULA AR, EPSTEIN LH, PERKINS KA, SAYLOR S: Different methods of assessing nicotine-induced antinociception may engage different neural mechanisms. Psychopharmacology (1995) 122:301–306.
   PubMed Web of Science ®Google Scholar
• DAMAJ MI, FEIYIN M, DUKAT M, GLASSCO W GLENNON RA, MARTIN BR: Antinociceptive responses to nicotinic acetylcholine receptor ligands after systemic and intrathecal administration in mice. Pharmacol Exp. Ther. (1998) 284:1058–1065.
   PubMed Web of Science ®Google Scholar
• ••Provides a thorough evaluation of the effectsof a variety of nAChR agonists after spinal or systemic administration. It also demonstrates that the nAChR agonists differ in their sensitivities to the nAChR antagonists mecarnylarnine and DHI3E.
   Google Scholar
• MILGROM-FRIEDMAN J, PENMAN R, MEARES R: A preliminary study on pain perception and tobacco smoking. Clin. Expel: Pharmacol Physiol. (1983) 10:161–169.
   PubMed Web of Science ®Google Scholar
• POMERLEAU OF, TURK DC, FERTIG JB: The effects of cigarette smoking on pain and anxiety. Addict. Behav (1984) 9:265–271.
   PubMed Web of Science ®Google Scholar
• FERTIG JB, POMERLEAU OF, SANDERS B: Nicotine-produced antinociception in minimally deprived smokers and ex-smokers. Addict. Behav. (1986) 11:239–248.
   PubMed Web of Science ®Google Scholar
• POMERLEAU OF: Nicotine as a psychoactive drug: anxiety and pain reduction. Psychopharmacol Bull. (1986) 22:865–869.
   PubMed Web of Science ®Google Scholar
• JAMNER LD, GIRDLER SS, SHAPIRO D, JARVIK ME: Pain inhibition, nicotine, and gender. Exp. Clin. Psychophannacol (1998) 6:96–106.
   PubMed Web of Science ®Google Scholar
• •This clinical study provides an analysis of the role of gender in responses to nicotine using an experimental pain model. It also demonstrates that the efficacy achieved with nicotine is comparable to that achieved with some analgesics.
   Google Scholar
• BADIO B, DALY JW: Epibatidine, a potent analgetic and nicotinic agonist. Pharmacol (1994) 45:563–569.
   Web of Science ®Google Scholar
• DALY JW, GARRAFFO HM, SPANDE TF, DECKER MW, SULLIVAN JP, WILLIAMS M: Alkaloids from frog skin: the discovery of epibatidine and the potential for developing novel non-opioid analgesics. Natural Prod. Rep. (2000) 17:131–135.
   PubMed Web of Science ®Google Scholar
• ••Daly details his discovery of epibatidinebeginning with the isolation of the alkaloid from frog skin in the 1970s.
   Google Scholar
• FLORES CM: The promise and pitfalls of a nicotinic cholinergic approach to pain management. Pain (2000) 88:1–6.
   PubMed Web of Science ®Google Scholar
• DECKER MW, MEYER MD: Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics. Biochem. Pharmacol (1999) 58:917–923.
   PubMed Web of Science ®Google Scholar
• DECKER MW, MEYER MD, SULLIVAN JP: The therapeutic potential of nicotinic acetylcholine receptor agonists for pain control. Expert Opin. Investig. Drugs (2001) 10:1819–1830.
   PubMed Web of Science ®Google Scholar
• CHANGEUX J-P: The nicotinic acetylcholine receptor: an allosteric protein prototype of ligand-gated ion channels. Trends Pharmacol Sci. (1990) 11:485–491.
   PubMed Web of Science ®Google Scholar
• BOYD RT: The molecular biology of neuronal nicotinic acetylcholine receptors. Crit. Rev Toxicol. (1997) 27:299–318.
   PubMed Web of Science ®Google Scholar
• GOTTI C, FORNASARI D, CLEMENTI F: Human neuronal nicotinic receptors. Frog. Neuronic]. (1997) 53:199–237.
   Google Scholar
• CORRINGER PJ, LE NOVERE N, CHANGEUX JP: Nicotinic receptors at the amino acid level. Ann. Rev Pharmacol. Toxicol (2000) 40:431–458.
   PubMed Web of Science ®Google Scholar
• CHEN DN, PATRICK JVV: The a-bungarotwdn-binding nicotinic acetylcholine-receptor from rat-brain contains only the a7 subunit. Biol. Chem. (1997) 272:24024–24029.
   Web of Science ®Google Scholar
• DRISDEL RC, GREEN WN: Neuronal a-bungarotoxin receptors are a7 subunit homomers. Neurosci. (2000) 20:133–139.
   Web of Science ®Google Scholar
• FLORES CM, ROGERS SW, PABREZA LA, WOLFE BB, KELLAR KJ: A subtype of nicotinic cholinergic receptor in rat brain is composed of a4 and in subunits and is upregulated by chronic nicotine treatment. MM. Pharmacol. (1992) 41:31–37.
   PubMed Web of Science ®Google Scholar
• FLORES CM, DECAMP RIVI, KILOS, ROGERS SW, HARGREAVES KM: Neuronal nicotinic receptor expression in sensory neurons of the rat trigeminal ganglion: demonstration of a3134, a novel subtype in the mammalian nervous system. Neurosci. (1996) 16:7892–7901.
   PubMed Web of Science ®Google Scholar
• ••This paper demonstrates the existence ofboth a4B2 and a34-containing nAChRs in the trigeminal ganglion.
   Google Scholar
• LIU L, CHANG CQ, RAO YQ, SIMON SA: Neuronal nicotinic acetylcholine receptors in rat trigeminal Ganglia. Brain Res. (1998) 809:238–245.
   PubMed Web of Science ®Google Scholar
• WANG N, ORR-URTREGER A, KORCZYN AD: The role of neuronal nicotinic acetylcholine receptor subunits in autonomic ganglia: lessons from knockout mice. Prog. Neurobiol (2002) 68:341–360.
   PubMed Web of Science ®Google Scholar
• SEGUELA P, WADICHE J, DINELEY-MILLER K, DANI JA, PATRICK JW: Molecular cloning, functional properties, and distribution of rat brain a7: a nicotinic cation channel highly permeable to calcium. NeuroscL (1993) 13:596–604.
   PubMed Web of Science ®Google Scholar
• WARD JM, COCKCROFT VB, LUNT GG, SMILLIE FS, WONNACOTT S: Methyllycaconitine: a selective probe for neuronal a-bungarotoxin binding sites. FEBS Lett. (1990) 270:45–48.
   PubMed Web of Science ®Google Scholar
• CHAVEZ-NORIEGA LE, CRONA JH, WASHBURN MS, URRUTIA A, ELLIOTT KJ, JOHNSON EC: Pharmacological characterization of recombinant human neuronal nicotinic acetylcholine receptors ha2132, ha2134, ha3132, ha3134, ha4132, ha4134 and ha7 expressed in Xenopus oocytes. Phannacol Exp. Ther. (1997) 280:346–356.
   PubMed Web of Science ®Google Scholar
• KEM WR, MAHNIR V, PAPKE RL, LINGLE CJ: Anabaseine is a potent agonist on muscle and neuronal a-bungarotoxin-sensitive nicotinic receptors. Phannacol Exp. Ther. (1997) 283:979–992.
   PubMed Web of Science ®Google Scholar
• CURZON P, NIKKEL AL, BANNON AW, ARNERIC SP, DECKER MW: Differences between the antinociceptive effects of the cholinergic channel activators A-85380 and (+/-)-epibatidine in rats. Phannacol Exp. Ther. (1998) 287:847–853.
   PubMed Web of Science ®Google Scholar
• •This paper reports on a direct comparison of the antinociceptive and locomotor effects of A-85380 and epibatidine and evaluates the role of the nucleus raphe magnus in mediating the antinociceptive effects of these two compounds.
   Google Scholar
• BANNON AW, DECKER MW, CURZON P et al: ABT-594 I(/0-5-(2-azetidinylmethoxy)-2-chloropyridinel - a novel, orally effective antinociceptive agent acting via neuronal nicotinic acetylcholine receptors. II. In vivo characterization. Phannacol Exp. Ther. (1998) 285:787–794.
   PubMed Web of Science ®Google Scholar
• IWAMOTO ET: Characterization of the antinociception induced by nicotine in the pedunculopontine tegmental nucleus and the nucleus raphe magnus. Phannacol Exp. Ther. (1990) 257:120–133.
   Web of Science ®Google Scholar
• ••This paper identifies brain stem nuclei thatmediate at least some of the antinociceptive effects of nAChR stimulation.
   Google Scholar
• BANNON AW, DECKER MW, HOLLADAY MW et al.: Broad spectrum, non-opioid analgesic activity by selective modulation of neuronal nicotinic acetylcholine receptors. Science (1998) 279:77–81.
   PubMed Web of Science ®Google Scholar
• ••This paper provides the first description of thebroad-spectrum antinociceptive activity of the novel nAChR agonist ABT-594 in rats.
   Google Scholar
• DECKER MW, CURZON P, HOLLADAY MW et al.: The role of neuronal nicotinic acetylcholine receptors in antinociception: effects of ABT-594. Physiol (1998) 92:221–224.
   Web of Science ®Google Scholar
• BITNER RS, NIKKEL AL, CURZON P, ARNERIC SP, BANNON AW, DECKER MW: Role of the nucleus raphe magnus in antinociception produced by ABT-594 - immediate early gene responses possibly linked to neuronal nicotinic acetylcholine receptors on serotonergic neurons. Neurosci. (1998) 18:5426–5432.
   PubMed Web of Science ®Google Scholar
• •This paper demonstrates that serotonergic neurons in the brain express the a4 subunit of the nAChR.
   Google Scholar
• ROLE LW, BERG DK: Nicotinic receptors in the development and modulation of CNS synapses. Neuron (1996) 16:1077–1085.
   PubMed Web of Science ®Google Scholar
• WONNACOTT S: Presynaptic nicotinic ACh receptors. Trends Neurosci. (1997) 20:92–98.
   PubMed Web of Science ®Google Scholar
• BLEDNOV YA, STOFFEL M, ALVA H, HARRIS RA: A pervasive mechanism for analgesia: activation of GIRK2 channels. PNAS (2003) 100:277–282.
   PubMed Web of Science ®Google Scholar
• ROGERS DT, IWAMOTO ET: Multiple spinal mediators in parenteral nicotine-induced antinociception. Phannacol Exp. Ther. (1993) 267:341–349.
   PubMed Web of Science ®Google Scholar
• ••This is the first demonstration that the effectsof systemically administered nicotine can be attenuated by spinal adminstration of a variety of neurotransmitter antagonists, confirming that nAChR agonists indirectly activate multiple spinal systems with analgesic activity
   Google Scholar
• RUETER LE, MEYER MD, DECKER MW: Spinal mechanisms underlying A-85380-induced effects on acute thermal pain. Brain Res. (2000) 872:93–101.
   PubMed Web of Science ®Google Scholar
• CHIARI A, TOBIN JR, PAN H-LMD, HOOD DD, EISENACH JC: Sex differences in cholinergic analgesia I: a supplemental nicotinic mechanism in normal females. Anesthesiology (1999) 91:1447–1454.
   PubMed Web of Science ®Google Scholar
• RUETER LE, KOHLHAAS KL, CURZON P, SUROWY CS, MEYER MD: Peripheral and central sites of action for A-85380 in the spinal nerve ligation model of neuropathic pain. Pain (2003) 103:269–276.
   PubMed Web of Science ®Google Scholar
• LAVAND'HOMME PM, EISENACH JC: Sex differences in cholinergic analgesia II: differing mechanisms in two models of allodynia. Anesthesiology (1999) 91:1455–1461.
   PubMed Web of Science ®Google Scholar
• RASHID MH, UEDA H: Neuropathy-specific analgesic action of intrathecal nicotinic agonists and its spinal GABA-mediated mechanism. Brain Res. (2002) 953:53–62.
   PubMed Web of Science ®Google Scholar
• RAO TS, CORREA LD, REID RT, LLOYD GK: Evaluation of anti-nociceptive effects of neuronal nicotinic acetylcholine receptor (nAChR) ligands in the rat tail-flick assay. Neurophannacology (1996) 35:393–405.
   PubMed Web of Science ®Google Scholar
• DAMAJ MI, MEYER EM, MARTIN BR: The antinociceptive effects of a7 nicotinic agonists in an acute pain model. Neurophannacology (2000) 39:2785–2791.
   PubMed Web of Science ®Google Scholar
• WANG H, YU M, OCHANI M et al.: Nicotinic acetylcholine receptor a7 subunit is an essential regulator of inflammation. Nature (2003) 421:384–388.
   PubMed Web of Science ®Google Scholar
• ••This paper provides evidence that the a7nAChR plays an important role in neural modulation of inflammatory processes occuring in the periphery.
   Google Scholar
• MARUBIO LM, ARROYO-JIMENEZ MD, CORDERO-ERAUSQUIN M et al.: Reduced antinociception in mice lacking neuronal nicotinic receptor subunits. Nature (1999) 398:805–810.
   PubMed Web of Science ®Google Scholar
• ••This paper uses knockout mice todemonstrate the importance of nAChRs containing a4 and 132 in nicotine-induced antinociception.
   Google Scholar
• BITNER RS, NIKKEL AL, CURZON P et al.: Reduced nicotinic receptor-mediated antinociception following in vivo antisense knock-down in rat. Brain Res. (2000) 871:66–74.
   PubMed Web of Science ®Google Scholar
• BANNON AW, GUNTHER KL, DECKER MW: Is epibatidine really analgesic? Dissociation of the activity, temperature, and analgesic effects of (±)-epibatidine. Pharmacol Biochem. Behav (1995) 51:693–698.
   PubMed Web of Science ®Google Scholar
• DAMAJ MI, GLASSCO W, ACETO MD, MARTIN BR: Antinociceptive and pharmacological effects of metanicotine, a selective nicotinic agonist. Pharmacol Exp. Ther. (1999) 291:390–398.
   PubMed Web of Science ®Google Scholar
• •This paper provides a description of the antinociceptive effects of RJR-2403 (trans-metanicotine) in several rodent models.
   Google Scholar
• GHELARDINI C, GALEOTTI N, BARLOCCO D, BARTOLINI A: Antinociceptive profile of the new nicotinic agonist DBO-83. Drug Devel Res. (1997) 40:251–258.
   Web of Science ®Google Scholar
• FERRETTI G, DUKAT M, GIANNELLA M et al: Homoazanicotine: a structure-affinity study for nicotinic acetylcholine receptor (nACh) binding.Med. Chem. (2002) 45:4724–4731.
   Web of Science ®Google Scholar
• ACHESON RIVI, FERRIS MJ, SINCLAIR NM: Transformations involving the pyrrolidine ring of nicotine. j. Chem. Soc. Perkin Trans. I. (1980):579–585.
   Google Scholar
• BENCHERIF M, BYRD G, CALDWELL WS, HAYES JR, LIPPIELLO PM: Pharmacological characterization of RJR-2403: a nicotinic agonist with potential therapeutic benefit in the treatment of Alzheimer's disease. CNS Drug Reviews (1997) 3:325–345.
   Google Scholar
• BENCHERIF M, LOVETTE ME, FOWLER KW et al: RJR-2403: a nicotinic agonist with CNS selectivity I. In vitro characterization. .1 Pharmacol Exp. Ther: (1996) 279:1413–1421.
   Google Scholar
• CRAFT RM, MILHOLLAND RB: Sex differences in cocaine- and nicotine-induced antinociception in the rat. Brazil Res. (1998) 809:137–140.
   Google Scholar
• DAMAJ MI: Influence of gender and sex hormones on nicotine acute pharmacological effects in mice. Pharmacol Exp. Ther. (2001) 296:132–140.
   PubMed Web of Science ®Google Scholar
• •This paper examines gender differences in the antinociceptive potency of nicotine in ICR mice and evaluates the influence of sex hormones on nicotine effects.
   Google Scholar
• OBINU MC, REIBAUD M, MIQUET JM, PASQUET M, ROONEY T: Brain-selective stimulation of nicotinic receptors by TC-1734 enhances ACh transmission from frontoparietal cortex and memory in rodents. Frog. Neuro-Psychopharmacol Biol. Psychiatry (2002) 26:913–918.
   PubMed Web of Science ®Google Scholar
• BENCHERIF M, BANE AJ, MILLER CH, DULL GM, GATTO GJ: TC-2559: a novel orally active ligand selective at neuronal acetylcholine receptors. Eur. .1 Pharmacol (2000) 409:45–55.
   Google Scholar
• HOULIHAN LM, SLATER Y, GUERRA DL et al.: Activity of cytisine and its brominated isosteres on recombinant human a7, a432 and a434 nicotinic acetylcholine receptors. Neurochem. (2001) 78:1029–1043.
   PubMed Web of Science ®Google Scholar
• GILBERT SD, CLARK TM, FLORES CM: Antihyperalgesic activity of epibatidine in the formalin model of facial pain. Pain (2001) 89:159–165.
   PubMed Web of Science ®Google Scholar
• KESINGLAND AC, GENTRY CT, PANESAR MS et al.: Analgesic profile of the nicotinic acetylcholine receptor agonists, (+)-epibatidine and ABT-594 in models of persistent inflammatory and neuropathic pain. Pahl (2000) 86:113–118.
   Google Scholar
• LAWAND NB, LU Y, WESTLUND KN: Nicotinic cholinergic receptors: potential targets for inflammatory pain relief. Pain (1999) 80:291–299.
   PubMed Web of Science ®Google Scholar
• TRAYNOR JR: Epibatidine and pain. Br. Anaesth. (1998) 81:69–76.
   PubMed Web of Science ®Google Scholar
• •This is a thorough review of the effects of epibatidine in predinical pain models.
   Google Scholar
• SULLIVAN JP, BRIGGS CA, DONNELLY- ROBERTS D et al.: (±)-Epibatidine can differentially evoke responses mediated by putative subtypes of nicotinic acetylcholine receptors (nAChRs). Med. Chem. Res. (1994) 4:502–516.
   Google Scholar
• SULLIVAN JP, DECKER MW, BRIONI JDet al.: (±)-Epibatidine elicits a diversity of in vitro and in vivo effects mediated by nicotinic acetylcholine receptors. .1 Pharmacol Exp. Ther. (1994) 271:624–631.
   Google Scholar
• BADIO B, GARRAFFO HM, PLUMMER CV, PAD GETT WL, DALY JW: Synthesis and nicotinic activity of epiboxidine: an isoxazole analog of epibatidine. Eur.J Pharmacol (1997) 321:189–194.
   PubMed Web of Science ®Google Scholar
• ELLIS JL, HARMAN D, GONZALEZ J et al.: Development of muscarinic analgesics derived from epibatidine: role of the M4 receptor subtype. .1 Pharmacol Exp. Ther: (1999) 288:1143–1150.
   Google Scholar
• SPANG JE, BERTRAND S, WESTERA G, PATT JT, SCHUBIGER PA, BERTRAND D: Chemical modification of epibatidine causes a switch from agonist to antagonist and modifies its selectivity for neuronal nicotinic acetylcholine receptors. Chem. Biol. (2000) 7:545–555.
   PubMedGoogle Scholar
• SHARPLES CGV, KAISER S, SOLIAKOV L et al: UB-165: a novel nicotinic agonist with subtype selectivity implicates the a432 subtype in the modulation of dopamine release from rat striatal synaptosomes. .1 NeuroscL (2000) 20:2783–2791.
   Google Scholar
• COX CD, MALPASS JR, GORDON J, ROSEN A: Synthesis of epibatidine isomers: endo-5- and 6-(6'-chloropyridy1)-2-azabicyclo[2.2.1]heptanes. .1 Chem. Soc. Perkin Trans. I. (2001):2372–2379.
   Google Scholar
• HODGSON DM, MAXWELL CR, WISEDALE R et al.: 6-Substituted 2-azabicyclo [2.2.11hept-5-enes by nitrogen-directed radical rearrangement: synthesis of an epibatidine analogue with high binding affinity at the nicotinic acetylcholine receptor. I Chem. Soc. Perkin Trans. I. (2001):3150–3158.
   Google Scholar
• BARLOCCO D, CIGNARELLA G, TONDI D et al.: Mono- and disubstituted-3, 8-diazabicyclo [3.2.11 octane derivatives as analgesics structurally related to epibatidine - synthesis, activity, and modeling. I Med. Chem. (1998) 41:674–681.
   Google Scholar
• TOMA L, QUADRELLI P, BUNNELLE WH et al.: 6-Chloropyridazin-3-y1 derivatives active as nicotinic agents: synthesis, binding, and modeling studies. J. Med. Chem. (2002) 45:4011–4017.
   PubMed Web of Science ®Google Scholar
• LIN N-H, LIY, HEY et al.: Synthesis and structure-activity relationships of 5-substituted pyridine analogues of 3- [2-(.5)-pyrrolidinyl)methoxylpyridine, A-84543: a potent nicotinic receptor ligand. Bioorg. Med. Chem. Lett. (2001) 11:631–633.
   Google Scholar
• ROMANELLI MN, MANETTI D, SCAPECCHI S et al.: Structure -affinity relationships of a unique nicotinic ligand: N-1 -dimethyl-N-4-phenylpiperazinium iodide (DMPP). I Med. Chem. (2001) 44:3946–3955.
   PubMed Web of Science ®Google Scholar
• SULLIVAN JP, DONNELLY-ROBERTS D,BRIGGS CA et al: A-85380 [342(.)-azetidinylmethoxy) pyridine]: M vitro pharmacological properties of a novel, high affinity a432 nicotinic acetylcholine receptor ligand. Neuropharmacology (1996) 35:725–734.
   Google Scholar
• DONNELLY-ROBERTS DL, PUTTFARCKEN PS, KUNTZWEILER TA et al.: ABT-594 RA-5-(2-azetidinylmethoxy)-2-chloropyridinel - a novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors. I In vitro characterization. I Pharmacol Exp. Ther. (1998) 285:777–786.
   PubMed Web of Science ®Google Scholar
• HOLLADAY MW, WASICAK JT, LIN NH et al.: Identification and initial structure-activity relationships of (A 5 (2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors. Med. Chem. (1998) 41:407–412.
   Web of Science ®Google Scholar
• HOLLADAY MW, DECKER MW: Discovery of ABT-594 and related neuronal nicotinic acetylcholine receptor modulators as analgesic agents: medicinal chemistry and biology. Adv. Med. Chem. (2000) 5:85–113.
   Google Scholar
• HOLLADAY MW, BAI H, LI YH et al: Structure-activity studies related to ABT-594, a potent non-opioid analgesic agent - effect of pyridine and azetidine ring substitutions on nicotinic acetylcholine receptor binding affinity and analgesic activity in mice. Biorganic Med. Chem. Lett. (1998) 8:2797–2802.
   PubMed Web of Science ®Google Scholar
• BANNON AW, DECKER MW, KIM DJB, CAMPBELL JE, ARNERIC SP: ABT-594, a novel cholinergic channel modulator, is efficacious in nerve ligation and diabetic neuropathy models of neuropathic pain. Brain Res. (1998) 801:158–163.
   PubMed Web of Science ®Google Scholar
• BOYCE S, WEBB JK, SHEPHEARD SL, RUSSELL MGN, HILL RG, RUPNIAK NMJ: Analgesic and toxic effects of ABT-594 resemble epibatidine and nicotine in rats. Pain (2000) 85:443–450.
   PubMed Web of Science ®Google Scholar
• DECKER MW, BANNON AW, BUCKLEY MJ et al.: Antinociceptive effects of the novel neuronal nicotinic acetylcholine receptor agonist, ABT-594, in mice. Eur. Pharmacol (1998) 346:23–33.
   PubMed Web of Science ®Google Scholar
• MEYER MD, DECKER MW, RUETER LE et al.: The identification of novel structural compound classes exhibiting high affinity for neuronal nicotinic acetylcholine receptors and analgesic efficacy in preclinical models of pain. Eur.j Pharmacol (2000) 393:171–177.
   PubMed Web of Science ®Google Scholar
• SORBERA LA, REVEL L, LEESON PA, CASTANERJ: ABT-594 - treatment of neuropathic pain - nicotinic agonist. Drugs of the Future (2001) 26:927–934.
   Web of Science ®Google Scholar
• LEE J, DAVIS CB, RIVERO R, REITZ AB, SHANK RP: Synthesis and structure-activity relationship of novel pyridyl ethers for the nicotinic receptor. Bioorg. Med. Chem. Lett. (2000) 10:1063–1066.
   PubMed Web of Science ®Google Scholar
• ELLIOTT RL, RYTHER KB, ANDERSON DJ et al: Novel 2-(2'-furo [3,2-blpyridinyl) pyrrolidines: potent neuronal nicotinic acetylcholine receptor ligands. Bioorg. Med. Chem. Lett. (1997) 7:2703–2708.
   Web of Science ®Google Scholar
• EFANGE SMN, TU Z, VON HOHENBERG K et al.: 2 (2 Piperidy1)- and 2-(2-pyrrolidinyl)chromans as nicotinic agonists: synthesis and preliminary pharmacological characterization. Med. Chem. (2001) 44:4704–4715.
   Google Scholar
• MULLEN G, NAPIER J, BALESTRA M et al.: (-)-Spiro [1-azabicyclo [2.2.21octane-3,5'-oxazolidin-2'-one], a conformationally restricted analog of acetylcholine, is a highly selective full agonist at the a7 nicotinic acetylcholine receptor. Med. Chem. (2000) 43:4045–4050.
   Google Scholar
• LEVIN ED, BETTEGOWDA C, BLOSSER J, GORDON J: AR-R 17779, an a7 nicotinic agonist, improves learning and memory in rats. Behav. PharmacoL (1999) 10:675–680.
   PubMed Web of Science ®Google Scholar
• GROTTICK AJ, TRUBE G, CORRIGALL WA et al.: Evidence that nicotinic a7 receptors are not involved in the hyperlocomotor and rewarding effects of nicotine. J. Pharmacol Exp. Ther. (2000) 294:1112–1119.
   PubMed Web of Science ®Google Scholar
• SCHREIBER R, DALMUS M, DE VRY J: Effects of a4/32- and a7-nicotine acetylcholine receptor agonists on prepulse inhibition of the acoustic startle response in rats and mice. Psychopharmacology (Berlin, Germany) (2002) 159:248–257.
   PubMed Web of Science ®Google Scholar
• ASTLES PC, BAKER SR, BOOT JR, BROAD LM, DELL CP, KEENAN M: Recent progress in the development of subtype selective nictoinic acetylcholine receptor ligands. Current Drug Targets - CNS & Neurological Disorders (2002) 1:337–348.
   PubMedGoogle Scholar
• BROAD LM, FELTHOUSE C, ZWART R et al: PSAB-OFP, a selective a7 nicotinic receptor agonist, is also a potent agonist of the 5-HT3 receptor. Eur. Pharmacol (2002) 452:137–144.
   PubMed Web of Science ®Google Scholar
• O'NEILL MJ, MOORE NA, MCKINZIE DL et al: Behavioural profiling of two potent a7 nicotinic acetylcholine receptor agonists. Soc. Neurosci. Meeting (2002) Abst.137.6.
   Google Scholar
• DE FILIPPI G, BROAD LM, ZWART R et al: Pharmacological characterization and M vitro physiological effects of new a7 nicotinic acetylcholine receptor agonists. Soc. Neurosci. Meeting (2002) Abst.137.5.
   Google Scholar
• HAMA A, MENZAGHI F: Antagonist of nicotinic acetylcholine receptors (nAChRs) enhances formalin-induced nociception in rats: tonic role of nAChRs in the control of pain following injury. Thalia Res. (2001) 888:102–106.
   Google Scholar
• CORDERO-ERAUSQUIN M, CHANGEUX J-P: Tonic nicotinic modulation of serotonergic transmission in the spinal cord. PNAS (2001) 98:2803–2807.
   PubMed Web of Science ®Google Scholar